Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07257770
Recruiting Not applicable

Local Treatment of Breast Pain Based on the Daily Use of a Topical Gel

NCT07257770 · tracked via the Priya Life Science Italy tracker
Sponsor
Lo.Li.Pharma s.r.l
Phase
Not applicable
Started
2025-09-11
Last updated
2026-02-13

Condition(s) studied

Mastalgia

Investigational drug(s) / intervention(s)

inositol

inositol: Topical application of a medical device based on inositol

Study summary

The trial aims to investigate the effect of a topical application of a medical device based on inositol in recovering breast pain

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Women aged between 18 and 70 years * Women who underwent breast surgery at least 15 days prior * Women experiencing breast pain associated with the surgical wound Exclusion Criteria: * Women under the age of 18 * Ongoing systemic and/or local pain therapy * Pregnant women

Primary outcome measure(s)

  • Reduction of breast pain — 3 months
    Breast pain is evaluated by using VAS (Visual Analogue Scale)

Trial sites (1)

FacilityCityRegionStatus
Policlinico Umberto I Roma Italy Recruiting

More Lo.Li.Pharma s.r.l trials in Italy

The Effect of the Association EGCG, Folic Acid and Vitamin B12 in Preventing the Persistence of HPV Infection. Recruiting
Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07257770 on ClinicalTrials.gov ↗ ← All trials in Italy